53. Sjogren syndrome Clinical trials / Disease details
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03627065 (ClinicalTrials.gov) | February 28, 2019 | 8/8/2018 | A Study of INCB050465 in Primary Sjögren's Syndrome | An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | Drug: Parsaclisib | Incyte Corporation | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |